$PVCT
PROVECTUS BIOPHARMACEUTICALS, INC. Stock $pvct

$pvct Overview Financials Valuation SEC Filings Company Website

2024 Q1 Form 10-K Financial Statement

#000149315224011699 Filed on March 28, 2024

Income Statement

Concept	2024 Q1	2023 Q4	2023
Revenue	$238.1K	$121.1K	$557.7K
YoY Change	16.12%	-26.53%	-43.61%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	-$47.63K	$225.4K	$1.345M
YoY Change	-112.6%	-27.18%	-10.52%
% of Gross Profit
Research & Development	$555.5K	$414.1K	$1.749M
YoY Change	1.3%	29.63%	-26.79%
% of Gross Profit
Depreciation & Amortization	$2.231K	-$1.080K	$8.921K
YoY Change	0.04%	-152.94%	-18.12%
% of Gross Profit
Operating Expenses	$685.3K	$641.7K	$3.459M
YoY Change	-30.58%	1.7%	-21.69%
Operating Profit	-$447.3K		-$2.901M
YoY Change	-42.82%		-15.36%
Interest Expense	-$56.93K	-$34.40K	$5.650K
YoY Change	25.84%	-29.04%	-103.46%
% of Operating Profit
Other Income/Expense, Net	-$56.78K	-$100.00	-$200.5K
YoY Change	25.5%	-85.07%	58.22%
Pretax Income	-$504.0K	-$663.4K	-$3.126M
YoY Change	-39.09%	-9.45%	-12.06%
Income Tax		$0.00
% Of Pretax Income
Net Earnings	-$504.0K	-$663.4K	-$3.102M
YoY Change	-39.09%	-9.45%	-12.74%
Net Earnings / Revenue	-211.72%	-547.77%	-556.16%
Basic Earnings Per Share	$0.00		-$0.01
Diluted Earnings Per Share	$0.00	$0.00	-$0.01
COMMON SHARES
Basic Shares Outstanding	419.5M shares	419.5M shares	419.5M shares
Diluted Shares Outstanding	419.5M shares		419.5M shares

Balance Sheet

Concept	2024 Q1	2023 Q4	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$18.04K	$76.58K	$76.58K
YoY Change	-47.17%	254.37%	254.37%
Cash & Equivalents	$18.04K	$76.58K	$76.58K
Short-Term Investments
Other Short-Term Assets	$990.7K	$1.288M	$1.288M
YoY Change	-36.52%	-31.4%	-31.4%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$1.009M	$1.365M	$1.365M
YoY Change	-36.77%	-28.14%	-28.14%
LONG-TERM ASSETS
Property, Plant & Equipment	$9.789K	$12.02K	$84.05K
YoY Change	-47.68%	-42.6%	-39.12%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$70.19K	$84.05K	$84.04K
YoY Change	-43.74%	-39.13%	-39.13%
TOTAL ASSETS
Total Short-Term Assets	$1.009M	$1.365M	$1.365M
Total Long-Term Assets	$70.19K	$84.05K	$84.04K
Total Assets	$1.079M	$1.449M	$1.449M
YoY Change	-37.28%	-28.88%	-28.88%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.370M	$1.676M	$1.676M
YoY Change	-28.19%	-19.98%	-19.98%
Accrued Expenses	$3.297M	$3.435M	$3.435M
YoY Change	13.14%	36.29%	36.29%
Deferred Revenue
YoY Change
Short-Term Debt	$3.134M	$0.00	$0.00
YoY Change
Long-Term Debt Due		$2.953M	$2.953M
YoY Change		42.86%	42.86%
Total Short-Term Liabilities	$8.516M	$9.017M	$9.017M
YoY Change	-1.67%	10.06%	10.06%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$12.73K	$25.30K	$25.30K
YoY Change	-79.38%	-65.52%	-65.52%
Total Long-Term Liabilities	$12.73K	$25.30K	$25.30K
YoY Change	-79.38%	-65.52%	-65.52%
TOTAL LIABILITIES
Total Short-Term Liabilities	$8.516M	$9.017M	$9.017M
Total Long-Term Liabilities	$12.73K	$25.30K	$25.30K
Total Liabilities	$8.529M	$9.042M	$9.042M
YoY Change	-2.22%	9.39%	9.39%
SHAREHOLDERS EQUITY
Retained Earnings	-$253.2M	-$252.7M
YoY Change	1.11%	1.24%
Common Stock	$419.5K	$419.5K
YoY Change	0.01%	0.01%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$7.450M	-$7.593M	-$7.593M
YoY Change
Total Liabilities & Shareholders Equity	$1.079M	$1.449M	$1.449M
YoY Change	-37.28%	-28.88%	-28.88%

Cashflow Statement

Concept	2024 Q1	2023 Q4	2023
OPERATING ACTIVITIES
Net Income	-$504.0K	-$663.4K	-$3.102M
YoY Change	-39.09%	-9.45%	-12.74%
Depreciation, Depletion And Amortization	$2.231K	-$1.080K	$8.921K
YoY Change	0.04%	-152.94%	-18.12%
Cash From Operating Activities	-$1.044M	-$562.0K	-$2.572M
YoY Change	67.36%	-25.54%	-15.44%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$781.1K	201.6K	$2.192M
YoY Change	51.46%	-57.49%	60.22%
NET CHANGE
Cash From Operating Activities	-$1.044M	-562.0K	-$2.572M
Cash From Investing Activities
Cash From Financing Activities	$781.1K	201.6K	$2.192M
Net Change In Cash	-$264.0K	-360.4K	-$404.9K
YoY Change	139.49%	28.43%	-75.83%
FREE CASH FLOW
Cash From Operating Activities	-$1.044M	-$562.0K	-$2.572M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023	us-gaap	Interest Paid Net InterestPaidNet		usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet		usd
CY2023	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
CY2022	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
CY2023	PVCT	Deposit Applied To Equity Issuances DepositAppliedToEquityIssuances		usd
CY2023	PVCT	Rightofuse Asset For Lease Liability RightofuseAssetForLeaseLiability		usd
CY2022	PVCT	Conversion Of2022 Notes And Related Accrued Interest To Series D1 Preferred Stock ConversionOf2022NotesAndRelatedAccruedInterestToSeriesD1PreferredStock		usd
CY2023	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit		usd
CY2022	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit		usd
CY2023	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit		usd
CY2022	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit		usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2023Q4	us-gaap	Deferred Tax Assets Charitable Contribution Carryforwards DeferredTaxAssetsCharitableContributionCarryforwards		usd
CY2023Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet		usd
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet		usd
CY2023	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability		usd
CY2023	dei	Document Type DocumentType	10-K
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-12-31
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	001-36457
CY2023	dei	Entity Registrant Name EntityRegistrantName	PROVECTUS BIOPHARMACEUTICALS, INC.
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	90-0031917
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	800 S Gay St
CY2023	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 1610
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	Knoxville
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	TN
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	37929
CY2023	dei	City Area Code CityAreaCode	866
CY2023	dei	Local Phone Number LocalPhoneNumber	594-5999
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Public Float EntityPublicFloat	45528616	usd
CY2024Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	419522119	shares
CY2023	dei	Auditor Firm AuditorFirmId	688
CY2023	dei	Auditor Name AuditorName	Marcum LLP
CY2023	dei	Auditor Location AuditorLocation	Los Angeles, CA
CY2023Q4	us-gaap	Cash Cash	76576	usd
CY2022Q4	us-gaap	Cash Cash	21605	usd
CY2023Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	950223	usd
CY2022Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	1410102	usd
CY2023Q4	us-gaap	Receivables Net Current ReceivablesNetCurrent	476	usd
CY2022Q4	us-gaap	Receivables Net Current ReceivablesNetCurrent	394	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	337522	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	467081	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	1364797	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	1899182	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	110994	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	102073	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	12020	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	20941	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	72026	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	117123	usd
CY2023Q4	us-gaap	Assets Assets	1448843	usd
CY2022Q4	us-gaap	Assets Assets	2037246	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1675891	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2094258	usd
CY2023Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	953248	usd
CY2022Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	1510958	usd
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	3240436	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	2404012	usd
CY2023Q4	us-gaap	Interest Payable Current InterestPayableCurrent	22600	usd
CY2022Q4	us-gaap	Interest Payable Current InterestPayableCurrent	30844	usd
CY2023Q4	PVCT	Interest Payable To Related Parties Current InterestPayableToRelatedPartiesCurrent	123828	usd
CY2022Q4	PVCT	Interest Payable To Related Parties Current InterestPayableToRelatedPartiesCurrent	40992	usd
CY2023Q4	us-gaap	Notes Payable To Bank Current NotesPayableToBankCurrent	277815	usd
CY2022Q4	us-gaap	Notes Payable To Bank Current NotesPayableToBankCurrent	239394	usd
CY2023Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	800000	usd
CY2022Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	625000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	25299	usd
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	25000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	25000000	shares
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	1000000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	1000000000	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	419522119	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	419522119	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	419447119	shares
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	419522	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	419497	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	244714967	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	242954193	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-60165	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-35679	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-252690409	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-249588641	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-7593351	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-6228510	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1448843	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	2037246	usd
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	557710	usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	989042	usd
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1749240	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2389360	usd
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1709720	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2027628	usd
CY2023	us-gaap	Operating Expenses OperatingExpenses	3458960	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	4416988	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-2901250	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-3427946	usd
CY2023	PVCT	Research And Development Tax Credit ResearchAndDevelopmentTaxCredit	-15696	usd
CY2022	PVCT	Research And Development Tax Credit ResearchAndDevelopmentTaxCredit	-36954	usd
CY2023	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-216214	usd
CY2022	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-163691	usd
CY2023	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-200518	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-126737	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-3101768	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-3554683	usd
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.01
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.01
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.01
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.01
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	419508146	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	419508146	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	419470338	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	419470338	shares
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-3101768	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-3554683	usd
CY2023	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Before Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax	-24486	usd
CY2022	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Before Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax	-1212	usd
CY2023	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-3126254	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-3555895	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-4187280	usd
CY2022	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	150000	usd
CY2022	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	3025	usd
CY2022	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	1361640	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-3554683	usd
CY2022	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-1212	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-6228510	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-6228510	usd
CY2023	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	2850	usd
CY2023	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	945464	usd
CY2023	PVCT	Stock Issued During Period Value Conversion Of Series D One Preferred Stock StockIssuedDuringPeriodValueConversionOfSeriesDOnePreferredStock	813099	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-3101768	usd
CY2023	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-24486	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-7593351	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-7593351	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-3101768	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-3554683	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	2850	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	3025	usd
CY2023	PVCT	Noncash Lease Expense NoncashLeaseExpense	45097	usd
CY2022	PVCT	Noncash Lease Expense NoncashLeaseExpense	52883	usd
CY2023	us-gaap	Depreciation Depreciation	8921	usd
CY2022	us-gaap	Depreciation Depreciation	10895	usd
CY2023	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	82	usd
CY2022	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	-4481	usd
CY2023	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-451425	usd
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-122914	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	-418370	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	807073	usd
CY2023	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-557710	usd
CY2022	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-989042	usd
CY2023	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	836426	usd
CY2022	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	402390	usd
CY2023	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-44422	usd
CY2022	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-58262	usd
CY2023	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	205655	usd
CY2022	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	156854	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2571978	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-3041472	usd
CY2023	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	800000	usd
CY2022	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	625000	usd
CY2023	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	1675000	usd
CY2022	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	1002500	usd
CY2023	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	283445	usd
CY2022	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	259659	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	2191555	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1367841	usd
CY2023	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-24485	usd
CY2022	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-1604	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-404908	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-1675235	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	1431707	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	3106942	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	1026799	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	1431707	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	76576	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	21605	usd
CY2023Q4	us-gaap	Restricted Cash RestrictedCash	950223	usd
CY2022Q4	us-gaap	Restricted Cash RestrictedCash	1410102	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	1026799	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	1431707	usd
CY2022	PVCT	Deposit Applied To Equity Issuances DepositAppliedToEquityIssuances	-150000	usd
CY2022	PVCT	Rightofuse Asset For Lease Liability RightofuseAssetForLeaseLiability	130443	usd
CY2023	PVCT	Conversion Of Notes And Related Accrued Interest ConversionOfNotesAndRelatedAccruedInterest	945467	usd
CY2022	PVCT	Conversion Of Notes And Related Accrued Interest ConversionOfNotesAndRelatedAccruedInterest	1361640	usd
CY2023	PVCT	Conversion Of2022 Notes And Related Accrued Interest To Series D1 Preferred Stock ConversionOf2022NotesAndRelatedAccruedInterestToSeriesD1PreferredStock	813098	usd
CY2023	PVCT	Purchase Of Insurance Policies Financed By Shortterm Note Payable PurchaseOfInsurancePoliciesFinancedByShorttermNotePayable	-306050	usd
CY2022	PVCT	Purchase Of Insurance Policies Financed By Shortterm Note Payable PurchaseOfInsurancePoliciesFinancedByShorttermNotePayable	-203175	usd
CY2023	us-gaap	Nature Of Operations NatureOfOperations	<p id="xdx_800_eus-gaap--NatureOfOperations_zg7iurdfYeC5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>1. <span id="xdx_82E_zt3TMF7V5zM9">Business Organization and Nature of Operations</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Provectus Biopharmaceuticals, Inc., a Delaware corporation (together with its subsidiary Provectus Biopharmaceuticals Australia Pty Ltd, “Provectus” or “the Company”), is a clinical-stage biotechnology company developing immunotherapy medicines for different diseases that are based on a class of synthetic small molecule immuno-catalysts called halogenated xanthenes (“HXs”). Our lead HX molecule is named rose bengal sodium (“RBS”).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s proprietary, patented, pharmaceutical-grade RBS is the active pharmaceutical ingredient in the drug product candidates of our current clinical development programs and the preclinical formulations of our current drug discovery programs. Importantly, our pharmaceutical-grade RBS displays different therapeutic effects at different concentrations and can be formulated for delivery by different routes of administration.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company believes that RBS targets disease in a bifunctional manner. First, direct contact may lead to cell death or repair, depending on the disease being treated and the concentration of the RBS utilized in the treatment. Second, multivariate immune signaling, activation, and response may follow that may manifest as stimulatory, inhibitory, or both.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company believes that it is the first entity to advance an RBS formulation into clinical trials for the treatment of a disease, such as those trials reported on the clinical trials registry at ClinicalTrials.gov.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company believes that it is the first and only entity to date to make pharmaceutical-grade RBS successfully, reproducibly, and consistently at a purity of nearly 100%.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s small molecule HX medical science platform comprises several different drug product candidates and preclinical pharmaceutical-grade RBS formulations using different concentrations delivered by different routes of administration specific to each disease area and/or indication. The Company’s HX medical science platform includes clinical development programs in oncology, dermatology, and ophthalmology; <i>in vivo</i> proof-of-concept programs in oncology, hematology, wound healing, and animal health; and <i>in vitro</i> drug discovery programs in infectious diseases and tissue regeneration and repair.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Risks and Uncertainties</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To date, the Company has not generated any revenues or profits from planned principal operations. The Company’s activities are subject to significant risks and uncertainties, including failing to successfully develop and license or commercialize the Company’s prescription drug candidates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	1026799	usd
CY2023Q4	us-gaap	Restricted Cash RestrictedCash	950223	usd
CY2023Q4	PVCT	Working Capital Deficit WorkingCapitalDeficit	7652098	usd
CY2022Q4	PVCT	Working Capital Deficit WorkingCapitalDeficit	6293198	usd
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_84C_eus-gaap--UseOfEstimates_zOabt6mQv2l3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_860_zNanLwach9k9">Use of Estimates</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in conformity with accounting principles generally accepted in the United States (“GAAP”) requires management to make estimates, judgments and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The Company’s significant estimates and assumptions include the recoverability and useful lives of long-lived assets, stock-based compensation, accrued liabilities and the valuation allowance related to the Company’s deferred tax assets.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2021Q4	PVCT	Proceeds From Grant Award For Study Of Animal Cancer And Dermatological ProceedsFromGrantAwardForStudyOfAnimalCancerAndDermatological	2500000	usd
CY2021Q4	PVCT	Payment To Vendors For Expense And Deposits PaymentToVendorsForExpenseAndDeposits	1549777	usd
CY2023Q4	us-gaap	Notes Payable NotesPayable	277815	usd
CY2022Q4	us-gaap	Notes Payable NotesPayable	239394	usd
CY2023	us-gaap	Interest Expense InterestExpense	5650	usd
CY2022	us-gaap	Interest Expense InterestExpense	3409	usd
CY2023	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p id="xdx_846_eus-gaap--ConcentrationRiskCreditRisk_zNDUhyVEXjmk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_86A_zxXogzic4J43">Cash Concentrations</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash and restricted cash are maintained at financial institutions and, at times, balances may exceed federally insured limits of $<span id="xdx_901_eus-gaap--CashFDICInsuredAmount_iI_c20231231_zbqEC6KEunvc" title="Insured limits">250,000</span>, although the Company seeks to minimize this through treasury management. The Company has never experienced any losses related to these balances although no assurance can be provided that it will not experience any losses in the future. As of December 31, 2023 and 2022, the Company had cash and restricted cash balances in excess of FDIC insurance limits of $<span id="xdx_90C_eus-gaap--FDICIndemnificationAsset_iI_c20231231_z2XDaohfKIg1" title="Cash in excess FDIC insured amount">776,799</span> and $<span id="xdx_908_eus-gaap--FDICIndemnificationAsset_iI_c20221231_zOkZQjLlTHQa" title="Cash in excess FDIC insured amount">1,181,707</span>, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023Q4	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	250000	usd
CY2023Q4	us-gaap	Fdic Indemnification Asset FDICIndemnificationAsset	776799	usd
CY2022Q4	us-gaap	Fdic Indemnification Asset FDICIndemnificationAsset	1181707	usd
CY2023Q4	us-gaap	Allowance For Doubtful Accounts Premiums And Other Receivables AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables	0	usd
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Premiums And Other Receivables AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables	0	usd
CY2023	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	130311698	shares
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	120375901	shares
CY2023Q4	PVCT	Foreign Currency Translation Adjustments Of Assets ForeignCurrencyTranslationAdjustmentsOfAssets	13916	usd
CY2023Q4	PVCT	Foreign Currency Translation Adjustments Of Liabilities ForeignCurrencyTranslationAdjustmentsOfLiabilities	389540	usd
CY2022Q4	PVCT	Foreign Currency Translation Adjustments Of Assets ForeignCurrencyTranslationAdjustmentsOfAssets	17373	usd
CY2022Q4	PVCT	Foreign Currency Translation Adjustments Of Liabilities ForeignCurrencyTranslationAdjustmentsOfLiabilities	383447	usd
CY2023	PVCT	Foreign Currency Translation Adjustment Of Expense And Other Income ForeignCurrencyTranslationAdjustmentOfExpenseAndOtherIncome	9763	usd
CY2022	PVCT	Foreign Currency Translation Adjustment Of Expense And Other Income ForeignCurrencyTranslationAdjustmentOfExpenseAndOtherIncome	4503	usd
CY2023Q4	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	719460	usd
CY2022Q4	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	314160	usd
CY2023Q4	us-gaap	Accrued Vacation Current AccruedVacationCurrent	92985	usd
CY2022Q4	us-gaap	Accrued Vacation Current AccruedVacationCurrent	69077	usd
CY2023Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	2330589	usd
CY2022Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1945589	usd
CY2023Q4	PVCT	Accrued Other Expenses AccruedOtherExpenses	97402	usd
CY2022Q4	PVCT	Accrued Other Expenses AccruedOtherExpenses	75186	usd
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	3240436	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	2404012	usd
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	0	usd
CY2023Q4	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions	3225000	shares
CY2023	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2	P1Y10M24D
CY2023	us-gaap	Professional Fees ProfessionalFees	254400	usd
CY2022	us-gaap	Professional Fees ProfessionalFees	254400	usd
CY2023	us-gaap	Officers Compensation OfficersCompensation	385000	usd
CY2022	us-gaap	Officers Compensation OfficersCompensation	385000	usd
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	2330589	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1945589	usd
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	1000000000	shares
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	25000000	shares
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q4	PVCT	Preferred Stock Shares Undesignated PreferredStockSharesUndesignated	1385000	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3625000	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.32
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	200000	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	0.86
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3425000	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.29
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	200000	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	0.67
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3225000	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.27
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P2Y1M9D
CY2022	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	670693	usd
CY2023	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	-704628	usd
CY2022	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	670693	usd
CY2023Q4	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions	3225000	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	512500	shares
CY2021Q4	PVCT	Weighted Average Exercise Price Outstanding WeightedAverageExercisePriceOutstanding	0.92
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Forfeitures And Expirations ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations	37500	shares
CY2022	PVCT	Weighted Average Exercise Price Forfeited WeightedAverageExercisePriceForfeited	0.29
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	475000	shares
CY2022Q4	PVCT	Weighted Average Exercise Price Outstanding WeightedAverageExercisePriceOutstanding	0.97
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Forfeitures And Expirations ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations	62500	shares
CY2023	PVCT	Weighted Average Exercise Price Forfeited WeightedAverageExercisePriceForfeited	0.29
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	412500	shares
CY2023Q4	PVCT	Weighted Average Exercise Price Outstanding WeightedAverageExercisePriceOutstanding	1.07
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Remaining Contractual Terms ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms	P0Y4M17D
CY2023Q4	PVCT	Share Based Compensation Arrangement By Share Based Payment Award Non Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue	0	usd
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	412500	shares
CY2023	PVCT	Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Exercisable Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm2	P0Y4M17D
CY2023Q4	PVCT	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber	412500	shares
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-3116233	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-3550182	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-9762	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-4501	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-3125995	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-3554683	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.2100	pure
CY2023	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-566183	usd
CY2022	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	538915	usd
CY2023	PVCT	Effective Income Tax Rate Reconciliation State And Local Deferred Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalDeferredIncomeTaxes	0.0514	pure
CY2023	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-138445	usd
CY2022	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	131778	usd
CY2023	PVCT	Effective Income Tax Rate Reconciliation Federal State And Local Income Taxes EffectiveIncomeTaxRateReconciliationFederalStateAndLocalIncomeTaxes	0.2614	pure
CY2023	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	-704628	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.051	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.051	pure
CY2023	PVCT	Effective Income Tax Rate Reconciliation Permanent Differences EffectiveIncomeTaxRateReconciliationPermanentDifferences	-0.029	pure
CY2022	PVCT	Effective Income Tax Rate Reconciliation Permanent Differences EffectiveIncomeTaxRateReconciliationPermanentDifferences	-0.037	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.225	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.186	pure
CY2023	PVCT	Effective Income Tax Rate Reconciliation Prior Year Trueup EffectiveIncomeTaxRateReconciliationPriorYearTrueup	-0.038	pure
CY2022	PVCT	Effective Income Tax Rate Reconciliation Prior Year Trueup EffectiveIncomeTaxRateReconciliationPriorYearTrueup	-0.023	pure
CY2023	PVCT	Effective Income Tax Rate Reconciliation Expiration Of State Net Operating Loss Carry Forwards Percentage EffectiveIncomeTaxRateReconciliationExpirationOfStateNetOperatingLossCarryForwardsPercentage	0.102	pure
CY2022	PVCT	Effective Income Tax Rate Reconciliation Expiration Of State Net Operating Loss Carry Forwards Percentage EffectiveIncomeTaxRateReconciliationExpirationOfStateNetOperatingLossCarryForwardsPercentage	0.491	pure
CY2023	PVCT	Effective Income Tax Rate Reconciliation Expiration Of Warrants And Options EffectiveIncomeTaxRateReconciliationExpirationOfWarrantsAndOptions	0.011	pure
CY2022	PVCT	Effective Income Tax Rate Reconciliation Expiration Of Warrants And Options EffectiveIncomeTaxRateReconciliationExpirationOfWarrantsAndOptions	0.010	pure
CY2023	PVCT	Effective Income Tax Rate Reconciliation Miscellaneous EffectiveIncomeTaxRateReconciliationMiscellaneous	-0.010	pure
CY2022	PVCT	Effective Income Tax Rate Reconciliation Miscellaneous EffectiveIncomeTaxRateReconciliationMiscellaneous	0.006	pure
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.000	pure
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.000	pure
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	41888685	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	42012057	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	3350278	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	3229869	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	118855	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	152813	usd
CY2023Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	425259	usd
CY2022Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	337558	usd
CY2023Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	817239	usd
CY2022Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	358897	usd
CY2022Q4	us-gaap	Deferred Tax Assets Charitable Contribution Carryforwards DeferredTaxAssetsCharitableContributionCarryforwards	10062	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense DeferredTaxAssetsTaxDeferredExpense	833876	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense DeferredTaxAssetsTaxDeferredExpense	628265	usd
CY2023Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	47434192	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	46729521	usd
CY2023Q4	PVCT	Deferred Tax Liabilities Depreciation DeferredTaxLiabilitiesDepreciation	2622	usd
CY2022Q4	PVCT	Deferred Tax Liabilities Depreciation DeferredTaxLiabilitiesDepreciation	3915	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities Prepaid Expenses DeferredTaxLiabilitiesPrepaidExpenses	87794	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Prepaid Expenses DeferredTaxLiabilitiesPrepaidExpenses	86459	usd
CY2023Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	90416	usd
CY2022Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	90374	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	47343776	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	46639147	usd
CY2023	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	-704628	usd
CY2022	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	670693	usd
CY2023Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	20100000	usd
CY2023	us-gaap	Income Tax Examination Description IncomeTaxExaminationDescription	the U.S. federal and Tennessee tax years open to examination are 2020 through 2023. The Australia income tax return remains open to examination for 2021 through 2023.
CY2023	us-gaap	Operating Lease Payments OperatingLeasePayments	44422	usd
CY2022	us-gaap	Operating Lease Payments OperatingLeasePayments	62944	usd
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	130422	usd
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P1Y6M
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y6M
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.050	pure
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	50663	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	25669	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	76332	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	2955	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	73377	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	48077	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	25299	usd
CY2023	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	0	usd
CY2022	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	0	usd
CY2021Q4	PVCT	Proceeds From Grant Award For Study Of Animal Cancer And Dermatological ProceedsFromGrantAwardForStudyOfAnimalCancerAndDermatological	2500000	usd
CY2023Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	953248	usd
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	557710	usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	989042	usd
CY2022Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	1510958	usd
CY2023	PVCT	License Transaction Description LicenseTransactionDescription	The Company completed the arrangements of this collaboration during the third quarter of 2022, whereby the Company paid $5,000 for the option that expires on May 31, 2023; agreed to pay up to $10,000 of new UM patent expenses for this IP during the period of the option and up to $25,000 of past UM patent expenses for this IP; and entered into a sponsored research agreement with UM on September 16, 2022 to study the combination of OBC’s PDAT and TOP PV-305, a formulation of the Company’s pharmaceutical-grade RBS, for the treatment of infectious keratitis.

Files In Submission

Name	View Source	Status
0001493152-24-011699-index-headers.html	Edgar Link	pending
0001493152-24-011699-index.html	Edgar Link	pending
0001493152-24-011699.txt	Edgar Link	pending
0001493152-24-011699-xbrl.zip	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32.htm	Edgar Link	pending
ex4-5.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-k.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
pvct-20231231.xsd	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
pvct-20231231_cal.xml	Edgar Link	unprocessable
pvct-20231231_def.xml	Edgar Link	unprocessable
pvct-20231231_pre.xml	Edgar Link	unprocessable
form10-k_htm.xml	Edgar Link	completed
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
pvct-20231231_lab.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$PVCT
PROVECTUS BIOPHARMACEUTICALS, INC. Stock $pvct

2024 Q1 Form 10-K Financial Statement

#000149315224011699 Filed on March 28, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PVCT PROVECTUS BIOPHARMACEUTICALS, INC. Stock $pvct

2024 Q1 Form 10-K Financial Statement

#000149315224011699 Filed on March 28, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PVCT
PROVECTUS BIOPHARMACEUTICALS, INC. Stock $pvct